Literature DB >> 23271584

Clinical characteristics of cough mixture abusers referred to three substance abuse clinics in Hong Kong: a retrospective study.

A K Tang1, W K Tang, H J Liang, F Chan, S C Mak, G S Ungvari.   

Abstract

OBJECTIVES. Cough mixture is the third most commonly abused substance in patients attending the Prince of Wales Hospital Substance Abuse Clinic. The content of the local cough mixture is not well researched. Paranoid psychosis manifesting as persecutory delusions and derogatory hallucination, as well as mood symptoms, is common in these patients. The natural history and outcome of such psychoses associated with cough mixture abuse are not well known. This study aimed to address these questions. METHODS. This was a retrospective study of cough mixture abuse in Hong Kong. Case records of cough mixture abusers currently receiving treatment at the 3 substance abuse clinics at the Prince of Wales Hospital, Alice Ho Miu Ling Nethersole Hospital, and the North District Hospital were retrieved for data collection. The patients' demographic data, duration and intake pattern of cough mixture, and use of any other drugs were documented. The presenting psychopathology, first urine toxicology results, diagnosis, treatment, number of hospitalizations, and course of the illness were also recorded. RESULTS. A total of 63 patients with the diagnosis of cough mixture abuse were identified in the database; 89% were male. The mean +/- SD age of the patients was 34.4 +/- 6.2 years; 67% were single and 83% were unemployed. The mean +/- SD age of onset of cough mixture abuse was 20 +/- 5 years. Psychiatric symptoms developed a mean +/- SD of 7.6 +/- 6.0 years after onset of abuse. According to the ICD-10 Mental and Behavioural Disorders criteria, the top psychiatric diagnoses were substance-induced psychotic disorder (67%), schizophrenia (19%), depressive disorder (11%), and dysthymia (10%). The most common ingredients in the urine sample at first presentation were promethazine (75%), pseudoephedrine (67%), codeine (60%), ephedrine (57%), zopiclone (17%), and hydrocodone (16%). Additionally, 16% of patients were in the priority follow-up group. The mean +/- SD follow-up period was 6.2 +/- 7.1 years during which there were 3.2 +/- 3.7 episodes of hospitalizations, with a mean +/- SD length of stay in each admission of 25.0 +/- 40.9 days. CONCLUSIONS. Promethazine, ephedrine, pseudoephedrine, codeine, and hydrocodone are the most common ingredients of cough mixture abused in this locality. Psychotic disorders are the most frequent psychiatric diagnosis associated with cough mixture abuse.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23271584

Source DB:  PubMed          Journal:  East Asian Arch Psychiatry        ISSN: 2078-9947


  4 in total

1.  Repeated, high-dose dextromethorphan treatment decreases neurogenesis and results in depression-like behavior in rats.

Authors:  Kai Ting Po; Andrew Man-Hong Siu; Benson Wui-Man Lau; Jackie Ngai-Man Chan; Kwok-Fai So; Chetwyn C H Chan
Journal:  Exp Brain Res       Date:  2015-05-05       Impact factor: 1.972

2.  Larger corpus callosum and reduced orbitofrontal cortex homotopic connectivity in codeine cough syrup-dependent male adolescents and young adults.

Authors:  Ying-Wei Qiu; Xiao-Fei Lv; Gui-Hua Jiang; Huan-Huan Su; Xiao-Fen Ma; Jun-Zhang Tian; Fu-Zhen Zhuo
Journal:  Eur Radiol       Date:  2016-06-21       Impact factor: 5.315

3.  Beyond the 'purple drank': Study of promethazine abuse according to the European Medicines Agency adverse drug reaction reports.

Authors:  Stefania Chiappini; Fabrizio Schifano; John Martin Corkery; Amira Guirguis
Journal:  J Psychopharmacol       Date:  2021-01-10       Impact factor: 4.153

Review 4.  In search of an ideal drug for safer treatment of obesity: The false promise of pseudoephedrine.

Authors:  Antonio Munafò; Stefano Frara; Andrea Giustina; Renato Bernardini; Norberto Perico; Rosaria Di Mauro; Monica Cortinovis; Chiara Burgaletto; Giuseppina Cantarella; Giuseppe Remuzzi
Journal:  Rev Endocr Metab Disord       Date:  2021-05-04       Impact factor: 6.514

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.